EUVIMEDEUVIMED entdecken
Crossref

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, Keun-Wook Lee, Matthew Ch Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster, Sang Cheul Oh, Yeul Hong Kim und 20 weitere

ONCOLOGY · 12.04.2023 · (3704) · 176-183

DOI: 10.46883/2023.25920992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ONCOLOGY, online erschienen am 27.04.2023. Verfasst von Daniel Vt Catenacci und 31 weiteren Autor:innen. Hauptthemen laut MEDLINE: Adenocarcinoma, Circulating Tumor DNA, Stomach Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCirculating Tumor DNAStomach NeoplasmsHumansBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesRetrospective StudiesTrastuzumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

gastric/gastroesophageal adenocarcinoma; HER2; ctDNA; and margetuximab plus pem…

Substanzen

Biomarkers, TumorCirculating Tumor DNAErb-b2 Receptor Tyrosine KinasesTrastuzumabmargetuximabAntibodies, MonoclonalpembrolizumabAntibodies, Monoclonal, HumanizedERBB2 protein, human

Zitieren

APA

Catenacci, D. V., Kang, Y. K., Uronis, H. E., Lee, K. W., Ng, M. C., Enzinger, P. C., Park, S. H., Gold, P. J., Lacy, J., Hochster, H. S., Oh, S. C., Kim, Y. H., Marrone, K. A., Kelly, R. J., Juergens, R. A., Kim, J. G., Alcindor, T., Sym, S. J., Song, E. K., …, & Park, H. (2023). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. ONCOLOGY, 176-183. https://doi.org/10.46883/2023.25920992

Vancouver

Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, et al. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. ONCOLOGY. 2023:176-183. doi:10.46883/2023.25920992

BibTeX
@article{Catenacci2023,
  author = {Catenacci, Daniel Vt and Kang, Yoon-Koo and Uronis, Hope E and Lee, Keun-Wook and Ng, Matthew Ch and Enzinger, Peter C and Park, Se Hoon and Gold, Philip J and Lacy, Jill and Hochster, Howard S and Oh, Sang Cheul and Kim, Yeul Hong and Marrone, Kristen A and Kelly, Ronan J and Juergens, Rosalyn A and Kim, Jong Gwang and Alcindor, Thierry and Sym, Sun Jin and Song, Eun-Kee and Chee, Cheng Ean and Chao, Yee and Kim, Sunnie and Oh, Do-Youn and Yen, Jennifer and Odegaard, Justin I and Lagow, Errin and Li, Daner and Sun, Jichao and Kaminker, Patrick and Moore, Paul A and Rosales, Minori Koshiji and Park, Haeseong},
  title = {Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma},
  journal = {ONCOLOGY},
  year = {2023},
  number = {3704},
  pages = {176--183},
  doi = {10.46883/2023.25920992}
}
Kostenlos starten →